Index, I have the same feedback from friends. They know
Index, I have the same feedback from friends. They know I've made a 900% gain on CYDY from my average and tell them this is just only the beginning of the beginning. I even spoke with them just recently that we completed our submission of our BLA, all three parts and that doesn't move them to pull the trigger. I have also explained to them the MOA and asked them to research to see if they can find another current or clinical potential drug that has advanced as far as CYDY has. They still won't pull the trigger.
Lastly, I've explained that we have so, so many catalysts that can possibly come our way from Combo/Mono to GVHD, 22 cancers, Immuno- diseases, and so forth and so forth and they just don't get it period!
I get it but no one else gets it and I'm talking about 13 others including my brother who claims that 3.00 is as far as it will climb and he too won't pull the trigger to buy.
So, I feel ya and what you too are going through to pass on such a great company in the making so, don't worry. Just remember who you recommended CYDY too and when we get to where we all believe we are going to with Leronlimab, JUST remember, you did inform them about it as you drive by their homes with your Lincoln, Lexus, Caddy or Bentley, okay?
GLTU and stay with all of us longs as we will reap what has been sown
HCIT
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
An Unyielding Growth Trajectory Hagerty, Inc. just unveiled its behemoth third quarter results for 2026 and they're nothing if not eye-popping. With a whopping 18% increase in written premium year-over-year to a towering $1,099 million, there's no mistaking Hagerty’s robust growth trajectory. And that's just one piece of the puzzle—earned premiums rocketed up by 42%...
Continue Reading
Investors ready for solid insights from M-tron The quiet whispers of impending deals and candid discussions are what really fuel the grind of stock market exchanges. Come November 16, at the Raymond James Investor-Led Sonoma Small Cap Symposium, you can bet your last nickel that M-tron Industries, Inc. (NYSE American: MPTI) will be making waves by doling out their future...
Continue Reading
Cerbo Enhances Telehealth With AI Scribe Expansion The digital healthcare playground looks like it's getting a nudge toward efficiency with Cerbo's latest move. Just when you thought telehealth couldn't get much sharper, these folks have drawn a line in the sand with their AI Scribe, which now makes its presence felt in virtual visits. No more juggling a dozen screens...
Continue Reading
A New Era for Lending Documentation If you've been drumming your fingers waiting on loan paperwork to get sorted, FileInvite's latest move might just be the caffeine kick the lending world needs. Announced at the NAGGL Annual Conference, their souped-up platform has been redesigned as the beating heart of lending documentation. This isn't just a facelift folks—it's an...
Continue Reading
HEMI V8 Legacy Reinvention at SEMA 2026 If you're the sort who gets their hands greasy restoring or revamping classic muscle, well, Direct Connection just made your life a whole lot easier. Stellantis' performance arm pulled the wraps off not just one, but six new HEMI V8 crate engine packages at the 2026 SEMA Show. Now, that's how you turn heads in Vegas. A New...
Continue Reading
Big Bucks for Cyber Missteps When it rains, it pours—or in the case of ILC Dover, it’s a downpour of $13 million they’re forking over to settle a gnarly cybersecurity debacle. If you blinked, you might miss this hefty payout marking the biggest recovery under the Department of Justice’s Civil Cybersecurity Fraud program. So, what's the fuss about? Well, it's got...
Continue Reading
LG's Strategic Battery Play You know it's serious when a company pushes into new territories with gusto. LG Energy Solution isn’t tiptoeing with their recent financials—Q3 2026 showed 'em raking in KRW 9.6 trillion in revenue. That's a mighty 27.6% uptick from the previous quarter, no small potatoes by any stretch, especially when their operating profit stands solid...
Continue Reading
Shaun Hughes Steps into Mace Consult's Financial Helm When a company like Mace Consult brings in someone with Shaun Hughes' pedigree as CFO, you know they're preparing for something big. This isn't exactly a cat nap in the park. With over two decades of driving financial strategy and performance across continents, Hughes isn't stepping into this role to twiddle his...
Continue Reading
CPQ Tech: Unpacking the 2026 Manufacturing Landscape In the cutthroat world of manufacturing, it's adapt or die. Right now, happens it's the fixers in Configure, Price, Quote (CPQ) technology, stepping in to save the day. Nucleus Research just dropped their 2026 Manufacturing CPQ Technology Value Matrix, shining a bright spotlight on who’s leading the pack and why it...
Continue Reading
A Banner Quarter for AMETEK Holy smokes, AMETEK has thrown down some numbers for the third quarter of 2026 that would make any seasoned trader sit up and take notice. We’re talking record-breaking across the board: $2.22 billion in sales, marking a whopping 17% increase over last year. Now, that's not just growth—that's rocket fuel. Earnings per share rocketed up with...
Continue Reading
